Login to Your Account



In the clinic


Thursday, July 10, 2014
Ario Pharma Ltd., of Cambridge, UK, said it started a phase IIa study of oral TRPV1 antagonist XEN-D0501 for the treatment and prevention of cough in patients with chronic idiopathic cough. About 20 patients will be enrolled in the trial and assigned to receive XEN-D0501 or placebo in a randomized, double-blinded, crossover design.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription